Rivoceranib

Phase 3Small molecule

EElevar Therapeutics

Rivoceranib is one of 71 small molecule programs targeting Thymic Epithelial Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thymic Epithelial TumorNot yet recruiting

Hepatocellular CarcinomaActive, not recruiting

CholangiocarcinomaRecruiting

Thymic Epithelial TumorPhase 2

Not yet recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

CholangiocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Rivoceranib

EElevar Therapeutics

Phase 3

3 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Viread

Gilead

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Coreg

Akero Therapeutics

Preclinical

2 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Vermox

WWim Janssens

Preclinical

1 9

Valemetostat

Bristol-Myers Squibb

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Thymic Epithelial Tumor

NCT06200233

Q3 2028

Phase 2Recruiting

Cholangiocarcinoma

NCT07105748

Not yet recruiting

Hepatocellular Carcinoma

NCT07147101

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04639180·687 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04985136·1 enrolled

Gastroesophageal Junction Cancer1 trial

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Terminated·EElevar Therapeutics·Phase 1/2·NCT03707028·12 enrolled

Metastatic Colorectal Cancer1 trial

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Terminated·EElevar Therapeutics·Phase 1·NCT04073615·29 enrolled

Cholangiocarcinoma1 trial

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Recruiting·FFudan University·Phase 2·NCT07105748·45 enrolled

ART1 trial

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Completed·EElevar Therapeutics·Phase 1·NCT05287360·60 enrolled

4 more indications

Thymic Epithelial Tumor1 trial

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Not yet recruiting·SSamsung Medical Center·Phase 2·NCT06200233·40 enrolled

Gastric Cancer1 trial

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Completed·EElevar Therapeutics·Phase 3·NCT03042611·460 enrolled

Olfactory Neuroblastoma1 trial

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT06308575

Adenoid Cystic Carcinoma1 trial

A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin

Terminated·EElevar Therapeutics·Phase 2·NCT04119453·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Rivoceranib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rivoceranib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rivoceranib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elevar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EElevar Therapeutics

Rivoceranib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Gastroesophageal Junction Cancer1 trial

Metastatic Colorectal Cancer1 trial

Cholangiocarcinoma1 trial

ART1 trial

Thymic Epithelial Tumor1 trial

Gastric Cancer1 trial

Olfactory Neuroblastoma1 trial

Adenoid Cystic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News